Business description
Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand.
Management board & Supervisory board
CEO |
Dr. Hans-Georg Feldmeier |
Management board |
Dr. Andreas Eberhorn, Christof Dreibholz |
Supervisory board |
Wilhelm Beier, Dr. Erwin Kern, Lothar Lanz |
Company data
Name: |
Dermapharm Holding SE |
Address: |
Lil-Dagover-Ring 7,D-82031 Grünwald |
Phone: |
+49-89-64186-0 |
Fax: |
+49-89-64186-130 |
E-mail: |
-
|
Internet: |
ir.dermapharm.de/index.php |
Industry: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Sub sector: |
Pharmaceuticals |
End of financial year: |
12-31 |
Free Float: |
- |
IPO date: |
2018-02-09 |
Investor relations
Name: |
Britta Hamberger |
IR phone: |
+49-89-64186-233 |
IR Fax: |
+49-89-64186-165 |
IR e-mail: |
ir@dermapharm.com
|